Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464864 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03464864 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 36 participants.
The verdict
NCT03464864, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
Interventions
- DRUG Treprostinil Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2018-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03464864
The ClinicalTrials.gov registry entry for NCT03464864 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treprostinil Inhalation Powder is the first listed.
NCT03464864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03464864 about?
NCT03464864 is a clinical study titled "Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers". A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
What is the current status of trial NCT03464864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-03-09. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT03464864?
The interventions under investigation include: Treprostinil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT03464864?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.